STAAR Surgical (NASDAQ:STAA) Major Shareholder Purchases $553,925.40 in Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. purchased 31,780 shares of STAAR Surgical stock in a transaction that occurred on Wednesday, April 2nd. The shares were bought at an average price of $17.43 per share, for a total transaction of $553,925.40. Following the completion of the transaction, the insider now owns 12,487,044 shares in the company, valued at $217,649,176.92. The trade was a 0.26 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Monday, March 31st, Broadwood Partners, L.P. purchased 22,189 shares of STAAR Surgical stock. The shares were purchased at an average price of $17.46 per share, with a total value of $387,419.94.
• On Thursday, March 27th, Broadwood Partners, L.P. bought 3,620 shares of STAAR Surgical stock. The stock was acquired at an average cost of $17.48 per share, for a total transaction of $63,277.60.
• On Tuesday, March 25th, Broadwood Partners, L.P. bought 34,296 shares of STAAR Surgical stock. The shares were acquired at an average price of $17.44 per share, with a total value of $598,122.24.
• On Thursday, March 20th, Broadwood Partners, L.P. bought 108,720 shares of STAAR Surgical stock. The stock was bought at an average cost of $17.96 per share, with a total value of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. bought 93,124 shares of STAAR Surgical stock. The shares were purchased at an average price of $17.54 per share, for a total transaction of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. acquired 249,503 shares of STAAR Surgical stock. The stock was purchased at an average price of $16.64 per share, with a total value of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. purchased 259,316 shares of STAAR Surgical stock. The shares were acquired at an average cost of $17.05 per share, with a total value of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. purchased 36,532 shares of STAAR Surgical stock. The stock was bought at an average price of $15.49 per share, for a total transaction of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. purchased 259,616 shares of STAAR Surgical stock. The stock was bought at an average cost of $14.96 per share, with a total value of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. acquired 8,221 shares of STAAR Surgical stock. The shares were purchased at an average cost of $21.50 per share, for a total transaction of $176,751.50.

STAAR Surgical Trading Down 1.1 %

NASDAQ STAA opened at $17.40 on Friday. The stock has a market cap of $858.26 million, a price-to-earnings ratio of -42.44 and a beta of 0.66. STAAR Surgical has a 12 month low of $13.50 and a 12 month high of $52.68. The company’s 50 day moving average is $18.99 and its two-hundred day moving average is $24.87.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Stifel Nicolaus decreased their price objective on shares of STAAR Surgical from $38.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday, February 12th. Mizuho downgraded shares of STAAR Surgical from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $45.00 to $17.00 in a research report on Wednesday, February 12th. Canaccord Genuity Group dropped their target price on shares of STAAR Surgical from $28.00 to $17.00 and set a “hold” rating on the stock in a report on Thursday, February 13th. William Blair lowered shares of STAAR Surgical from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 12th. Finally, Jefferies Financial Group cut STAAR Surgical from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $25.29.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Quarry LP bought a new position in shares of STAAR Surgical in the third quarter worth about $50,000. FMR LLC grew its holdings in STAAR Surgical by 79.3% during the 3rd quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier’s stock valued at $263,000 after buying an additional 3,136 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in STAAR Surgical in the 4th quarter valued at $180,000. HighTower Advisors LLC purchased a new stake in STAAR Surgical in the 3rd quarter worth $336,000. Finally, Bridgefront Capital LLC boosted its holdings in shares of STAAR Surgical by 27.2% during the 4th quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier’s stock valued at $262,000 after purchasing an additional 2,306 shares during the last quarter. Institutional investors own 96.70% of the company’s stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.